Exact Mass: 501.2363
Exact Mass Matches: 501.2363
Found 500 metabolites which its exact mass value is equals to given mass value 501.2363
,
within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error
0.01 dalton.
D-Glucosaminide
D-Glucosaminide is an intermediate in the Human Aminosugars metabolism, the substrate of the enzyme di-N-acetyl-chitobiase [EC:3.2.1.-], from the Glycosidases class (i.e.: enzymes hydrolyzing O- and S-glycosyl compounds). (KEGG) [HMDB] D-Glucosaminide is an intermediate in the Human Aminosugars metabolism, the substrate of the enzyme di-N-acetyl-chitobiase [EC:3.2.1.-], from the Glycosidases class (i.e.: enzymes hydrolyzing O- and S-glycosyl compounds). (KEGG).
Chitotriose
Chitotriose is an enzyme inhibitor. Chitotriose caused a strong reduction in the inhibitory effects of human lysozymes. (PMID: 2911608). Of several sugars and amino sugars tested, chitotriose caused greater than 90\\% inhibition of adherence to S-HA(Saliva supernatant protein). Chitotriose is an enzyme inhibitor. Chitotriose caused a strong reduction in the inhibitory effects of human lysozymes. (PMID: 2911608)
Fimasartan
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist Fimasartan (BR-A-657) is a non-peptide antagonist of the angiotensin receptor AT1, used to study hypertension and heart failure.
17-oxoyuzurimine|methyl (3S*,3aR*,5R*,5aS*,6S*,10aR*,11R*,12aS*,12bR*)-5-acetoxy-5a-(acetoxymethyl)-2,3,3a,5,5a,6,7,8,9,10,10a,11,12,12b-tetradecahydro-12b-hydroxy-3-methyl-9-oxo-4H-1,6-methanocyclopent[1,8]azuleno[4,3a-g]indole-11-carboxylate
alpha-L-Rhap-(1?3)-beta-D-GalpNAc-(1?1)-ribitol|OS I
c(Gly-Pro-Tyr-Leu-Ala)|cyclo(Ala-Gly-Pro-Tyr-Leu-)|cyclo(ProTyrLeuAlaGly)|pseudostellarin|pseudostellarin A
His Ala Phe Lys
Ala Phe His Lys
Ala Glu Pro Trp
Ala Glu Trp Pro
Ala Phe His Gln
Ala Phe Lys His
Ala Phe Gln His
Ala His Phe Lys
Ala His Phe Gln
Ala His Lys Phe
Ala His Gln Phe
Ala Lys Phe His
Ala Lys His Phe
Ala Pro Glu Trp
Ala Pro Trp Glu
Ala Gln Phe His
Ala Gln His Phe
Ala Gln Gln Arg
Ala Gln Arg Gln
Ala Arg Gln Gln
Ala Trp Glu Pro
Ala Trp Pro Glu
Cys Asp His Lys
Cys Asp Lys His
Cys His Asp Lys
Cys His Lys Asp
Cys His Arg Ser
Cys His Ser Arg
Cys Lys Asp His
Cys Lys His Asp
Cys Pro Pro Trp
Cys Pro Trp Pro
Cys Arg His Ser
Cys Arg Ser His
Cys Ser His Arg
Cys Ser Arg His
Cys Trp Pro Pro
Asp Cys His Lys
Asp Cys Lys His
Asp Asp Pro Arg
Asp Asp Arg Pro
Asp His Cys Lys
Asp His Lys Cys
Asp Lys Cys His
Asp Lys His Cys
Asp Pro Asp Arg
Asp Pro Arg Asp
Asp Arg Asp Pro
Asp Arg Pro Asp
Glu Ala Pro Trp
Glu Ala Trp Pro
Glu Glu Lys Pro
Glu Glu Pro Lys
Glu Glu Pro Gln
Glu Glu Gln Pro
Glu Lys Glu Pro
Glu Lys Pro Glu
Glu Pro Ala Trp
Glu Pro Glu Lys
Glu Pro Glu Gln
Glu Pro Lys Glu
Glu Pro Gln Glu
Glu Pro Arg Thr
Glu Pro Thr Arg
Glu Pro Trp Ala
Glu Gln Glu Pro
Glu Gln Pro Glu
Glu Arg Pro Thr
Glu Arg Thr Pro
Glu Thr Pro Arg
Glu Thr Arg Pro
Glu Trp Ala Pro
Glu Trp Pro Ala
Phe Ala His Lys
Phe Ala His Gln
Phe Ala Lys His
Phe Ala Gln His
Phe His Ala Lys
Phe His Ala Gln
Phe His Lys Ala
Phe His Gln Ala
Phe Lys Ala His
Phe Lys His Ala
Phe Gln Ala His
Phe Gln His Ala
His Ala Phe Gln
His Ala Lys Phe
His Ala Gln Phe
His Cys Asp Lys
His Cys Lys Asp
His Cys Arg Ser
His Cys Ser Arg
His Asp Cys Lys
His Asp Lys Cys
His Phe Ala Lys
His Phe Ala Gln
His Phe Lys Ala
His Phe Gln Ala
His Lys Ala Phe
His Lys Cys Asp
His Lys Asp Cys
His Lys Phe Ala
His Lys Met Ser
His Lys Ser Met
His Met Lys Ser
His Met Asn Thr
His Met Gln Ser
His Met Ser Lys
His Met Ser Gln
His Met Thr Asn
His Asn Met Thr
His Asn Thr Met
His Gln Ala Phe
His Gln Phe Ala
His Gln Met Ser
His Gln Ser Met
His Arg Cys Ser
His Arg Ser Cys
His Ser Cys Arg
His Ser Lys Met
His Ser Met Lys
His Ser Met Gln
His Ser Gln Met
His Ser Arg Cys
His Thr Met Asn
His Thr Asn Met
Ile Asn Gln Gln
Ile Pro Ser Trp
Ile Pro Trp Ser
Ile Gln Asn Gln
Ile Gln Gln Asn
Ile Ser Pro Trp
Ile Ser Trp Pro
Ile Trp Pro Ser
Ile Trp Ser Pro
Lys Ala Phe His
Lys Ala His Phe
Lys Cys Asp His
Lys Cys His Asp
Lys Asp Cys His
Lys Asp His Cys
Lys Glu Glu Pro
Lys Glu Pro Glu
Lys Phe Ala His
Lys Phe His Ala
Lys His Ala Phe
Lys His Cys Asp
Lys His Asp Cys
Lys His Phe Ala
Lys His Met Ser
Lys His Ser Met
Lys Met His Ser
Lys Met Ser His
Lys Pro Glu Glu
Lys Ser His Met
Lys Ser Met His
Leu Asn Gln Gln
Leu Pro Ser Trp
Leu Pro Trp Ser
Leu Gln Asn Gln
Leu Gln Gln Asn
Leu Ser Pro Trp
Leu Ser Trp Pro
Leu Trp Pro Ser
Leu Trp Ser Pro
Met His Lys Ser
Met His Asn Thr
Met His Gln Ser
Met His Ser Lys
Met His Ser Gln
Met His Thr Asn
Met Lys His Ser
Met Lys Ser His
Met Asn His Thr
Met Asn Thr His
Met Gln His Ser
Met Gln Ser His
Met Ser His Lys
Met Ser His Gln
Met Ser Lys His
Met Ser Gln His
Met Thr His Asn
Met Thr Asn His
Asn His Met Thr
Asn His Thr Met
Asn Ile Gln Gln
Asn Leu Gln Gln
Asn Met His Thr
Asn Met Thr His
Asn Asn Arg Val
Asn Asn Val Arg
Asn Gln Ile Gln
Asn Gln Leu Gln
Asn Gln Gln Ile
Asn Gln Gln Leu
Asn Arg Asn Val
Asn Arg Val Asn
Asn Thr His Met
Asn Thr Met His
Asn Val Asn Arg
Asn Val Arg Asn
Pro Ala Glu Trp
Pro Ala Trp Glu
Pro Cys Pro Trp
Pro Cys Trp Pro
Pro Asp Asp Arg
Pro Asp Arg Asp
Pro Glu Ala Trp
Pro Glu Glu Lys
Pro Glu Glu Gln
Pro Glu Lys Glu
Pro Glu Gln Glu
Pro Glu Arg Thr
Pro Glu Thr Arg
Pro Glu Trp Ala
Pro Ile Ser Trp
Pro Ile Trp Ser
Pro Lys Glu Glu
Pro Leu Ser Trp
Pro Leu Trp Ser
Pro Pro Cys Trp
Pro Pro Trp Cys
Pro Gln Glu Glu
Pro Arg Asp Asp
Pro Arg Glu Thr
Pro Arg Thr Glu
Pro Ser Ile Trp
Pro Ser Leu Trp
Pro Ser Trp Ile
Pro Ser Trp Leu
Pro Thr Glu Arg
Pro Thr Arg Glu
Pro Thr Val Trp
Pro Thr Trp Val
Pro Val Thr Trp
Pro Val Trp Thr
Pro Trp Ala Glu
Pro Trp Cys Pro
Pro Trp Glu Ala
Pro Trp Ile Ser
Pro Trp Leu Ser
Pro Trp Pro Cys
Pro Trp Ser Ile
Pro Trp Ser Leu
Pro Trp Thr Val
Pro Trp Val Thr
Gln Ala Phe His
Gln Ala His Phe
Gln Ala Gln Arg
Gln Ala Arg Gln
Gln Glu Glu Pro
Gln Glu Pro Glu
Gln Phe Ala His
Gln Phe His Ala
Gln His Ala Phe
Gln His Phe Ala
Gln Ile Asn Gln
Gln Ile Gln Asn
Gln Leu Asn Gln
Gln Leu Gln Asn
Gln Asn Ile Gln
Gln Asn Leu Gln
Gln Asn Gln Ile
Gln Asn Gln Leu
Gln Pro Glu Glu
Gln Gln Ala Arg
Gln Gln Ile Asn
Gln Gln Leu Asn
Gln Gln Asn Ile
Gln Gln Asn Leu
Gln Gln Gln Val
Gln Gln Arg Ala
Gln Gln Val Gln
Gln Arg Ala Gln
Gln Arg Gln Ala
Gln Val Gln Gln
Arg Ala Gln Gln
Arg Cys His Ser
Arg Cys Ser His
Arg Asp Asp Pro
Arg Asp Pro Asp
Arg Glu Pro Thr
Arg Glu Thr Pro
Arg His Cys Ser
Arg His Ser Cys
Arg Asn Asn Val
Arg Asn Val Asn
Arg Pro Asp Asp
Arg Pro Glu Thr
Arg Pro Thr Glu
Arg Gln Ala Gln
Arg Gln Gln Ala
Arg Ser Cys His
Arg Ser His Cys
Arg Thr Glu Pro
Arg Thr Pro Glu
Arg Val Asn Asn
Ser Cys His Arg
Ser Cys Arg His
Ser His Cys Arg
Ser His Lys Met
Ser His Met Lys
Ser His Arg Cys
Ser Ile Pro Trp
Ser Ile Trp Pro
Ser Lys His Met
Ser Lys Met His
Ser Leu Pro Trp
Ser Leu Trp Pro
Ser Met His Lys
Ser Met Lys His
Ser Pro Ile Trp
Ser Pro Leu Trp
Ser Pro Trp Ile
Ser Pro Trp Leu
Ser Arg Cys His
Ser Arg His Cys
Ser Trp Ile Pro
Ser Trp Leu Pro
Ser Trp Pro Ile
Ser Trp Pro Leu
Thr Glu Pro Arg
Thr Glu Arg Pro
Thr Pro Glu Arg
Thr Pro Arg Glu
Thr Pro Val Trp
Thr Pro Trp Val
Thr Arg Glu Pro
Thr Arg Pro Glu
Thr Val Pro Trp
Thr Val Trp Pro
Thr Trp Pro Val
Thr Trp Val Pro
Val Asn Asn Arg
Val Asn Arg Asn
Val Pro Thr Trp
Val Pro Trp Thr
Val Gln Gln Gln
Val Arg Asn Asn
Val Thr Pro Trp
Val Thr Trp Pro
Val Trp Pro Thr
Val Trp Thr Pro
Trp Ala Glu Pro
Trp Ala Pro Glu
Trp Cys Pro Pro
Trp Glu Ala Pro
Trp Glu Pro Ala
Trp Ile Pro Ser
Trp Ile Ser Pro
Trp Leu Pro Ser
Trp Leu Ser Pro
Trp Pro Ala Glu
Trp Pro Cys Pro
Trp Pro Glu Ala
Trp Pro Ile Ser
Trp Pro Leu Ser
Trp Pro Pro Cys
Trp Pro Ser Ile
Trp Pro Ser Leu
Trp Pro Thr Val
Trp Pro Val Thr
Trp Ser Ile Pro
Trp Ser Leu Pro
Trp Ser Pro Ile
Trp Ser Pro Leu
Trp Thr Pro Val
Trp Thr Val Pro
Trp Val Pro Thr
Trp Val Thr Pro
PC(8:2/8:2)
Chitotriose
An amino trisaccharide comprising of three 2-amino-2-deoxy-D-glucopyranose units joined by beta-(1->4) linkages.
2-N,2-N,7-N,7-N-tetraphenyl-9H-carbazole-2,7-diamine
Fimasartan
C - Cardiovascular system > C09 - Agents acting on the renin-angiotensin system > C09C - Angiotensin ii receptor blockers (arbs), plain > C09CA - Angiotensin ii receptor blockers (arbs), plain C78274 - Agent Affecting Cardiovascular System > C270 - Antihypertensive Agent > C66930 - Angiotensin II Receptor Antagonist Fimasartan (BR-A-657) is a non-peptide antagonist of the angiotensin receptor AT1, used to study hypertension and heart failure.
2-amino-2-deoxy-beta-D-glucopyranosyl-(1->4)-2-amino-2-deoxy-beta-D-glucopyranosyl-(1->4)-2-amino-2-deoxy-D-glucopyranose
N-[(3-methyl-1-phenyl-5-pyrrolidino-pyrazol-4-yl)methyleneamino]-2-(3-pyridyl)cinchoninamide
N-[(5S,6S,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-phenylbenzamide
3-(4-Morpholinyl)-5-[2-[4-[3-(3-pyridinyl)-1,2,4-triazol-1-yl]anilino]-4-pyrimidinyl]benzonitrile
N-[(5R,6R,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-phenylbenzamide
N-[(5R,6S,9R)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-phenylbenzamide
N-[(5R,6R,9S)-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-4-phenylbenzamide
N-[(5S,6S,9R)-8-[(3-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(2-pyridin-4-ylacetyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(2-phenylethyl)acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
(3R,6aR,8R,10aR)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aR,8R,10aR)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aR,8R,10aR)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aS,8S,10aS)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aR,8S,10aR)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aS,8S,10aS)-N-(4-fluorophenyl)-3-hydroxy-8-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aR,8R,10aR)-N-(4-fluorophenyl)-3-hydroxy-8-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aS,8R,10aS)-N-(4-fluorophenyl)-3-hydroxy-8-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(4-phenylphenyl)acetamide
2-[(3R,6aS,8R,10aS)-3-hydroxy-1-(pyridine-3-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(4-phenylphenyl)acetamide
N-[(5R,6R,9S)-8-[(3-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(2-pyridin-4-ylacetyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(2-phenylethyl)acetamide
2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(2-pyridin-4-ylacetyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-3-yl]-N-(2-phenylethyl)acetamide
(3R,6aS,8S,10aS)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aS,8R,10aS)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aR,8S,10aR)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aS,8R,10aS)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aS,8S,10aS)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aS,8R,10aS)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aR,8S,10aR)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aS,8R,10aS)-N-(4-fluorophenyl)-3-hydroxy-8-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aR,8R,10aR)-N-(4-fluorophenyl)-3-hydroxy-8-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
2-[(3R,6aR,8R,10aR)-3-hydroxy-1-(pyridine-3-carbonyl)-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(4-phenylphenyl)acetamide
N-[(5S,6R,9R)-8-[(2-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(5R,6S,9S)-8-[(2-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
1-[[(10S,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-phenylurea
1-[[(10S,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-phenylurea
2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
(3S,6aR,8S,10aR)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
2-[(3S,6aR,8S,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(4-phenylphenyl)acetamide
N-[(5R,6R,9R)-8-[(3-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(5R,6S,9R)-8-[(3-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(5S,6S,9S)-8-[(3-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(5S,6R,9R)-8-[(3-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(5R,6R,9R)-8-[(2-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(5R,6R,9S)-8-[(2-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(5S,6S,9R)-8-[(2-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
N-[(5S,6R,9S)-8-[(2-fluorophenyl)methyl]-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-2-methoxyacetamide
1-[[(10S,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-phenylurea
1-[[(10R,11S)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-phenylurea
2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(1-oxo-2-pyridin-4-ylethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(1S)-1-phenylethyl]acetamide
(3S,6aS,8S,10aS)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1S)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aS,8R,10aS)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aR,8R,10aR)-N-(3-chlorophenyl)-3-hydroxy-8-[2-oxo-2-[[(1R)-1-phenylethyl]amino]ethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3S,6aR,8S,10aR)-N-(4-fluorophenyl)-3-hydroxy-8-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
(3R,6aR,8S,10aR)-N-(4-fluorophenyl)-3-hydroxy-8-[2-[(2-methoxyphenyl)methylamino]-2-oxoethyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocine-1-carboxamide
2-[(3S,6aS,8R,10aS)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(4-phenylphenyl)acetamide
2-[(3S,6aS,8S,10aS)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(4-phenylphenyl)acetamide
2-[(3S,6aR,8R,10aR)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(4-phenylphenyl)acetamide
2-[(3R,6aR,8S,10aR)-3-hydroxy-1-[oxo(pyridin-4-yl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(4-phenylphenyl)acetamide
1-[[(10R,11R)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-phenylurea
1-[[(10R,11S)-13-[(2S)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-phenylurea
1-[[(10R,11R)-13-[(2R)-1-hydroxypropan-2-yl]-11-methyl-14-oxo-9-oxa-13-azatricyclo[13.4.0.02,7]nonadeca-1(19),2,4,6,15,17-hexaen-10-yl]methyl]-1-methyl-3-phenylurea
2-[(3R,6aS,8S,10aS)-3-hydroxy-1-[oxo(3-pyridinyl)methyl]-3,4,6,6a,8,9,10,10a-octahydro-2H-pyrano[2,3-c][1,5]oxazocin-8-yl]-N-(4-phenylphenyl)acetamide
[1-[2-aminoethoxy(hydroxy)phosphoryl]oxy-3-propanoyloxypropan-2-yl] (4Z,7Z,10Z,13Z)-hexadeca-4,7,10,13-tetraenoate
1,2-di-(2E,4E-octadienoyl)-sn-glycero-3-phosphocholine
MePC(15:4)
Provides by LipidSearch Vendor. © Copyright 2006-2024 Thermo Fisher Scientific Inc. All rights reserved
(S,R)-GSK321
(S,R)-GSK321 is a potent, selective mutant IDH1 inhibitor with IC50 values of 2.9, 3.8, 4.6 and 46 nM for R132G, R132C, R132H and WT IDH1, respectively, and >100-fold selectivity over IDH2. (S,R)-GSK321 induces decrease in intracellular 2-HG, abrogation of the myeloid differentiation block and induction of granulocytic differentiation at the level of leukemic blasts and more immature stem-like cells. (S,R)-GSK321can be used for research of acute myeloid leukemia (AML) and other cancers[1].
GSK321
GSK321 is a potent inhibitor of mutant isocitrate dehydrogenase 1 (IDH1) enzymes. GSK321 has high inhibitory and selectivity for mutant IDH1 enzymes. GSK321 can be used for the research of acute myeloid leukemia[1][2].